Health

Alliance for Regenerative Medicine Responds to EU Pharmaceutical Roadmap

Tuesday, July 7, 2020 - 7:00am

Leading international advocacy group calls for effective regulation, clinical trial support, and value-based reimbursement that benefits patient access to ATMPs

Key Points: 
  • Leading international advocacy group calls for effective regulation, clinical trial support, and value-based reimbursement that benefits patient access to ATMPs
    The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry.
  • It is critical that the EU Pharmaceutical Strategy furthers the ability of patients to benefit from these transformative therapies and supports vigorous growth in the ATMP sector to drive further advances.
  • ARM looks forward to further consultation on the EU Pharmaceutical Strategy.
  • For more information or for media requests, please contact Kaitlyn (Donaldson) Dupont from the Alliance for Regenerative Medicine at kdonaldson@alliancerm.org or Consilium Strategic Communications at ARM@consilium-comms.com .

Propeller Health Sensor to Be Co-Packaged With Recently Approved Enerzair® Breezhaler® Asthma Medication in Europe

Tuesday, July 7, 2020 - 6:30am

Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.

Key Points: 
  • Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.
  • View the full release here: https://www.businesswire.com/news/home/20200706005585/en/
    An industry first: Propeller Health digital health solution packaged and prescribed with Enerzair Breezhaler inhaler by Novartis.
  • Enerzair Breezhaler and Propeller sensor and app received approval from the European Commission on in July and will launch across Europe starting in 2020.
  • Healthcare professionals in Europe will have the option to prescribe Enerzair Breezhaler with or without the companion digital health platform.

Milken Institute Launches New Tool Providing a Holistic View of What Makes Communities More Vulnerable to COVID-19

Tuesday, July 7, 2020 - 5:01am

In response, the Milken Institute published an interactive COVID-19 Community Explorer , allowing users to determine what community-wide risk factors can make certain areas more vulnerable to the virus.

Key Points: 
  • In response, the Milken Institute published an interactive COVID-19 Community Explorer , allowing users to determine what community-wide risk factors can make certain areas more vulnerable to the virus.
  • View the full release here: https://www.businesswire.com/news/home/20200706005638/en/
    At this time, COVID-19 fatalities are disproportionately higher among Black and Latino populations, older adults, and individuals with hypertension and diabetes.
  • In developing this multimedia platform, the Milken Institute Research Department set out to understand what commonalities exist in communities more likely to see a potential resurgence with the virus.
  • Rather, it is a combination of factors in underserved communities that contribute to making some areas more vulnerable to the virus.

Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells

Tuesday, July 7, 2020 - 4:01am

"We are excited by these early data in very sick patients suffering from COVID-19 ARDS.

Key Points: 
  • "We are excited by these early data in very sick patients suffering from COVID-19 ARDS.
  • "We look forward to evaluating this promising therapy in the FDA-approved randomized, double-blinded, placebo-controlled clinical trial of cryopreserved, allogeneic, off-the-shelf, cord blood derived T-regulatory cells (CK0802) in intubated patients suffering from COVID-19 ARDS.
  • "We are very encouraged by these early clinical observations and remain fully committed to bring forward this promising, potentially life-saving therapy into market.
  • There were a total of 11,565,414 COVID-19 cases confirmed globally with 536,649 deaths (July 6, 2020), according to Johns Hopkins University data .

Dangers of Sharing a Toothbrush Highlight Need for Superb Dental Hygiene, says A-Z Dental Care

Tuesday, July 7, 2020 - 3:00am

Essentially, anyone sharing their toothbrush with another person is also sharing a wealth of microorganisms as well as potentially-contaminated bodily fluids.

Key Points: 
  • Essentially, anyone sharing their toothbrush with another person is also sharing a wealth of microorganisms as well as potentially-contaminated bodily fluids.
  • Los Angeles County-based A-Z Dental Care agrees, saying that to maintain a good standard of oral health, patients should only use their own toothbrush.
  • A-Z Dental Care says that as one final piece of advice, don't discount the benefit that routine preventive care with an outstanding dentist can provide.
  • Interested readers can learn more about A-Z Dental Care by visiting their website at https://www.atozdentalcare.com/ or by calling (626) 314-6908.

PHC Group Increases Stake in SciMed to Strengthen Life Sciences Business in Asia

Tuesday, July 7, 2020 - 2:00am

Located in Singapore, SciMed markets and distributes life sciences products and provides its services throughout Southeast Asia and India.

Key Points: 
  • Located in Singapore, SciMed markets and distributes life sciences products and provides its services throughout Southeast Asia and India.
  • PHCHD has positioned SciMed as the main distributor for their life sciences business across Southeast Asia and India, and has expanded its business in the region through their close partnership over 30 years.
  • This will provide additional market opportunities and increase penetration into countries such as India, which can further strengthen the life sciences business.
  • SciMed (Asia) Pte Ltd is a provider of products and services for biomedical, life sciences, healthcare, drug discovery, pharmaceutical, laboratories, industrial tests, and agricultural markets.

Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review

Tuesday, July 7, 2020 - 12:40am

OSAKA, Japan, July 6, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.

Key Points: 
  • OSAKA, Japan, July 6, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.
  • The substantive review, which traditionally spans 180 days from the FDA's receipt of the PMA final module, is an in-depth review following which the FDA will make a decision as to whether the PMA is approved.
  • As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices.
  • Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries.

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

Tuesday, July 7, 2020 - 12:50am

The aggregate gross proceeds to the Company of both offerings is expected to be approximately $8.0 million.

Key Points: 
  • The aggregate gross proceeds to the Company of both offerings is expected to be approximately $8.0 million.
  • As part of the offerings and subject to Nasdaq rules, the investor will have the right to designate two directors to the Companys Board of Directors.
  • The offerings are expected to close on or about July 8, 2020, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

Ancestry® COVID-19 Study Points to Gene Associated with Male Susceptibility to COVID-19

Tuesday, July 7, 2020 - 12:07am

Ancestrys scientists have identified a DNA region which may be associated with COVID-19 susceptibility near the IVNS1ABP gene.

Key Points: 
  • Ancestrys scientists have identified a DNA region which may be associated with COVID-19 susceptibility near the IVNS1ABP gene.
  • Our early analysis points to a gene called IVNS1ABP, that has previously been associated with influenza infections.
  • COVID-19 positive versus COVID-19 negative)
    Ancestry identified a DNA region that appears to be associated with COVID-19 susceptibility near the IVNS1ABP gene.
  • Ancestry scientists identified a DNA difference called rs6668622-T that is associated with 44% increased odds of COVID-19 susceptibility in males (Odds Ratio=1.44; P-value

Julius Group and Noble Biomaterials Announce New Strategic Partnership to Launch High-Quality Antiviral PPE for Consumers

Tuesday, July 7, 2020 - 12:00am

Amid the global pandemic, the companies are partnering to allow Julius Group to manufacture PPE using Noble Biomaterials powerful Ionic+ antimicrobial technology.

Key Points: 
  • Amid the global pandemic, the companies are partnering to allow Julius Group to manufacture PPE using Noble Biomaterials powerful Ionic+ antimicrobial technology.
  • These consumer products will be released through InnoTier, a company recently launched by Julius Group.
  • Leading companies such as 3M, Systagenix and KCI rely on the products manufactured by Noble Biomaterials for the medical market.
  • Julius Group is a leading innovative manufacturer that combines the latest technologies with heritage craftsmanship for gloves and fashion accessories production.